Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Miura, Seiki ^a   Mitsuhashi, Noboru ^a   Shimizu, Hiroaki ^a   Kimura, Fumio ^a   Yoshidome, Hiroyuki ^a   Otsuka, Masayuki ^a   Kato, Atsushi ^a   Shida, Takashi ^a   Okamura, Daiki ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MESSENGER RNA; FGF19 PROTEIN, HUMAN; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; TUMOR PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FIBROBLAST GROWTH FACTOR 19 GENE; FIBROBLAST GROWTH FACTOR RECEPTOR 4 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CANCER INVASION; DISEASE COURSE; DRUG EFFECT; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE;

AGED; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 84856565638     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-56     Document Type: Article

References (35)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543. 10.1016/S1470-2045(01)00486-7, 11905707.
2. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004, 127:S218-S224. 10.1053/j.gastro.2004.09.036, 15508087.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236. 10.1002/hep.20933, 16250051.
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
5. Chen YJ, Yeh SH, Chen JT, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000, 119:431-440. 10.1053/gast.2000.9373, 10930378.
6. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200-207.
7. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004, 20:563-569. 10.1016/j.tig.2004.08.007, 15475116.
8. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149. 10.1016/j.cytogfr.2005.01.001, 15863030.
9. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004, 306:1506-1507. 10.1126/science.1105396, 15567848.
10. Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4, 14)(p16.3, q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997, 90:4062-4070.
11. Zaharieva BM, Simon R, Diener PA, et al. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 2003, 201:603-608. 10.1002/path.1481, 14648664.
12. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8, 13) leukaemia/lymphoma syndrome. Nat Genet 1998, 18:84-87. 10.1038/ng0198-84, 9425908.
13. Shimokawa T, Furukawa Y, Sakai M, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. Cancer Res 2003, 63:6116-6120.
14. Ruohola JK, Viitanen TP, Valve EM, et al. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res 2001, 61:4229-4237.
15. Gowardhan B, Douglas DA, Mathers ME, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005, 92:320-327. 2361833, 15655558.
16. McLeskey SW, Ding IY, Lippman ME, et al. MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res 1994, 54:523-530.
17. Streit S, Bange J, Fichtner A, et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004, 111:213-217. 10.1002/ijc.20204, 15197773.
18. Qian ZR, Sano T, Asa SL, et al. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 2004, 89:1904-1911. 10.1210/jc.2003-031489, 15070963.
19. Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002, 62:840-847.
20. Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004, 10:6169-6178. 10.1158/1078-0432.CCR-04-0408, 15448004.
21. Spinola M, Leoni V, Pignatiello C, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005, 23:7307-7311. 10.1200/JCO.2005.17.350, 16061909.
22. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001, 2:REVIEWS3005. 138918, 11276432.
23. Harmer NJ, Pellegrini L, Chirgadze D, et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004, 43:629-640. 10.1021/bi035320k, 14730967.
24. Ornitz DM, Xu J, Colvin JS, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996, 271:15292-15297. 10.1074/jbc.271.25.15292, 8663044.
25. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003, 17:1581-1591. 10.1101/gad.1083503, 196131, 12815072.
26. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004, 145:2594-2603. 10.1210/en.2003-1671, 14976145.
27. Nicholes K, Guillet S, Tomlinson E, et al. Mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002, 160:2295-2307. 10.1016/S0002-9440(10)61177-7, 1850847, 12057932.
28. Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008, 27:85-97. 10.1038/sj.onc.1210623, 17599042.
29. Ho HK, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009, 50:118-127. 10.1016/j.jhep.2008.08.015, 19008009.
30. Arii S, Okamoto E, Imamura M. Registries in Japan: current status of hepatocellular carcinoma in Japan. Liver Cancer Study Group of Japan. Semin Surg Oncol 1996, 12:204-211. 10.1002/(SICI)1098-2388(199605/06)12:3<204::AID-SSU11>3.0.CO;2-X, 8727612.
31. Diaz D, Fabre I, Daujat M, et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990, 99:737-747.
32. Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003, 37:1105-1113. 10.1053/jhep.2003.50204, 12717391.
33. Li K, Lin SY, Brunicardi FC, et al. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 2003, 63:3593-3597.
34. Duxbury MS, Matros E, Ito H, et al. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg 2004, 240:667-674. discussion 675-666, 1356468, 15383794.
35. Cho-Rok J, Yoo J, Jang YJ, et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 2006, 43:1042-1052. 10.1002/hep.21137, 16628636.